Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Artif Organs ; 47(10): 1581-1591, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37395735

RESUMEN

BACKGROUND: Extracorporeal life support (ECLS) has extensive applications in managing patients with acute cardiac and pulmonary failure. Two primary modalities of ECLS, cardiopulmonary bypass (CPB) and extracorporeal membrane oxygenation (ECMO), include several similarities in their composition, complications, and patient outcomes. Both CPB and ECMO pose a high risk of thrombus formation and platelet activation due to the large surface area of the devices and bleeding due to system anticoagulation. Therefore, novel methods of anticoagulation are needed to reduce the morbidity and mortality associated with extracorporeal support. Nitric oxide (NO) has potent antiplatelet properties and presents a promising alternative or addition to anticoagulation with heparin during extracorporeal support. METHODS: We developed two ex vivo models of CPB and ECMO to investigate NO effects on anticoagulation and inflammation in these systems. RESULTS: Sole addition of NO as an anticoagulant was not successful in preventing thrombus formation in the ex vivo setups, therefore a combination of low-level heparin with NO was used. Antiplatelet effects were observed in the ex vivo ECMO model when NO was delivered at 80 ppm. Platelet count was preserved after 480 min when NO was delivered at 30 ppm. CONCLUSION: Combined delivery of NO and heparin did not improve haemocompatibility in either ex vivo model of CPB and ECMO. Anti-inflammatory effects of NO in ECMO systems have to be evaluated further.


Asunto(s)
Oxigenación por Membrana Extracorpórea , Trombosis , Humanos , Oxigenación por Membrana Extracorpórea/efectos adversos , Oxigenación por Membrana Extracorpórea/métodos , Óxido Nítrico/uso terapéutico , Puente Cardiopulmonar/efectos adversos , Puente Cardiopulmonar/métodos , Anticoagulantes/farmacología , Anticoagulantes/uso terapéutico , Heparina/farmacología , Heparina/uso terapéutico , Trombosis/etiología , Trombosis/prevención & control , Inflamación/etiología , Inflamación/prevención & control
2.
Genome Biol ; 24(1): 59, 2023 03 29.
Artículo en Inglés | MEDLINE | ID: mdl-36991492

RESUMEN

BACKGROUND: Genome-wide association studies (GWAS) have identified > 200 loci associated with breast cancer risk. The majority of candidate causal variants are in non-coding regions and likely modulate cancer risk by regulating gene expression. However, pinpointing the exact target of the association, and identifying the phenotype it mediates, is a major challenge in the interpretation and translation of GWAS. RESULTS: Here, we show that pooled CRISPR screens are highly effective at identifying GWAS target genes and defining the cancer phenotypes they mediate. Following CRISPR mediated gene activation or suppression, we measure proliferation in 2D, 3D, and in immune-deficient mice, as well as the effect on DNA repair. We perform 60 CRISPR screens and identify 20 genes predicted with high confidence to be GWAS targets that promote cancer by driving proliferation or modulating the DNA damage response in breast cells. We validate the regulation of a subset of these genes by breast cancer risk variants. CONCLUSIONS: We demonstrate that phenotypic CRISPR screens can accurately pinpoint the gene target of a risk locus. In addition to defining gene targets of risk loci associated with increased breast cancer risk, we provide a platform for identifying gene targets and phenotypes mediated by risk variants.


Asunto(s)
Estudio de Asociación del Genoma Completo , Neoplasias , Animales , Ratones , Repeticiones Palindrómicas Cortas Agrupadas y Regularmente Espaciadas , Predisposición Genética a la Enfermedad , Fenotipo , Polimorfismo de Nucleótido Simple
3.
Respiration ; 97(6): 525-539, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30731462

RESUMEN

BACKGROUND: Next-generation sequencing (NGS) in lung cancer specimens from endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is usually performed on formalin-fixed paraffin-embedded cell block material. OBJECTIVES: Since DNA can be damaged by this process, we investigated the potential of using DNA extracted from Diff-Quik cytology smears made for rapid on-site evaluation during EBUS-TBNA. METHODS: In a prospective study, 67 patients undergoing diagnostic EBUS-TBNA were ana-lysed. We compared cell blocks and smears for DNA yields and sequencing (TruSeq Amplicon Cancer Panel) outcomes. Smears were also evaluated for tumour cell fraction and overall cellularity (cell count). RESULTS: Primary lung cancer was diagnosed in 64 patients and metastatic malignancy in 3 patients. The DNA yield from smears was significantly higher than that obtained from matched cell blocks (mean 1,740 vs. 434 ng; p = 0.001). For 33 cases with matched smears and cell blocks the mutation profiles were similar. Smears with abundant malignant cells (using a cut-off of > 25% tumour cell fraction and > 1,000 cells) accurately predicted high (> 50 ng) DNA yield and therefore success in triaging samples to sequencing. In terms of tissue workflow, using only smears as source DNA for sequencing was an improvement in the use of only cell blocks (54/67 [80.6%] vs. 41/67 [61.2%]); however, the use of cell blocks when smears were not available or did not yield sufficient DNA further improved the success rate to 62/67 (92.5%) cases. CONCLUSION: We recommend smears in laboratory workflows as the primary source of DNA for NGS following an EBUS procedure.


Asunto(s)
Colorantes Azulados , Biopsia por Aspiración con Aguja Fina Guiada por Ultrasonido Endoscópico , Secuenciación de Nucleótidos de Alto Rendimiento , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patología , Azul de Metileno , Xantenos , Anciano , Anciano de 80 o más Años , Endosonografía , Femenino , Humanos , Ganglios Linfáticos/patología , Masculino , Persona de Mediana Edad , Estudios Prospectivos
4.
J Pathol ; 247(2): 214-227, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30350370

RESUMEN

Metaplastic breast carcinoma (MBC) is relatively rare but accounts for a significant proportion of global breast cancer mortality. This group is extremely heterogeneous and by definition exhibits metaplastic change to squamous and/or mesenchymal elements, including spindle, squamous, chondroid, osseous, and rhabdomyoid features. Clinically, patients are more likely to present with large primary tumours (higher stage), distant metastases, and overall, have shorter 5-year survival compared to invasive carcinomas of no special type. The current World Health Organisation (WHO) diagnostic classification for this cancer type is based purely on morphology - the biological basis and clinical relevance of its seven sub-categories are currently unclear. By establishing the Asia-Pacific MBC (AP-MBC) Consortium, we amassed a large series of MBCs (n = 347) and analysed the mutation profile of a subset, expression of 14 breast cancer biomarkers, and clinicopathological correlates, contextualising our findings within the WHO guidelines. The most significant indicators of poor prognosis were large tumour size (T3; p = 0.004), loss of cytokeratin expression (lack of staining with pan-cytokeratin AE1/3 antibody; p = 0.007), EGFR overexpression (p = 0.01), and for 'mixed' MBC, the presence of more than three distinct morphological entities (p = 0.007). Conversely, fewer morphological components and EGFR negativity were favourable indicators. Exome sequencing of 30 cases confirmed enrichment of TP53 and PTEN mutations, and intriguingly, concurrent mutations of TP53, PTEN, and PIK3CA. Mutations in neurofibromatosis-1 (NF1) were also overrepresented [16.7% MBCs compared to ∼5% of breast cancers overall; enrichment p = 0.028; mutation significance p = 0.006 (OncodriveFM)], consistent with published case reports implicating germline NF1 mutations in MBC risk. Taken together, we propose a practically minor but clinically significant modification to the guidelines: all WHO_1 mixed-type tumours should have the number of morphologies present recorded, as a mechanism for refining prognosis, and that EGFR and pan-cytokeratin expression are important prognostic markers. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias de la Mama/genética , Mutación , Neoplasias Complejas y Mixtas/genética , Antígenos CD/análisis , Biomarcadores de Tumor/análisis , Neoplasias de la Mama/química , Neoplasias de la Mama/clasificación , Neoplasias de la Mama/patología , Cadherinas/análisis , Fosfatidilinositol 3-Quinasa Clase I/genética , Estudios Transversales , Transición Epitelial-Mesenquimal , Receptores ErbB/análisis , Femenino , Predisposición Genética a la Enfermedad , Humanos , Queratinas/análisis , Metaplasia , Persona de Mediana Edad , Clasificación del Tumor , Neoplasias Complejas y Mixtas/química , Neoplasias Complejas y Mixtas/clasificación , Neoplasias Complejas y Mixtas/patología , Neurofibromina 1/genética , Fosfohidrolasa PTEN/genética , Fenotipo , Carga Tumoral , Proteína p53 Supresora de Tumor/genética
5.
Am J Respir Crit Care Med ; 196(3): 388-391, 2017 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-28762784
6.
Oncotarget ; 6(6): 3932-46, 2015 Feb 28.
Artículo en Inglés | MEDLINE | ID: mdl-25668816

RESUMEN

HER2-positive breast tumors are associated with a high risk of brain relapse. HER3 is thought to be an indispensible signaling substrate for HER2 (encoded by ERBB2) and is induced in breast cancer-brain metastases, though the molecular mechanisms by which this oncogenic dimer promotes the development of brain metastases are still elusive. We studied the effects of the HER3-HER2 ligand, heregulin (neuregulin-1, broadly expressed in the brain), on luminal breast cancer cell lines in vitro. Treatment of SKBr3 (ERBB2-amplified), MDA-MB-361 (ERBB2-amplified, metastatic brain tumor-derived) and MCF7 (HER2-positive, not ERBB2-amplified) cells with exogenous heregulin increased proliferation and adhesive potential, concomitant with induction of cyclin D1 and ICAM-1, and suppression of p27. All three cell lines invaded through matrigel toward a heregulin chemotactic signal in transwell experiments, associated with activation of extracellular cathepsin B and matrix metalloproteinase-9 (MMP-9). Moreover, heregulin induced breast cancer cell transmigration across a tight barrier of primary human brain microvascular endothelia. This was dependent on the activity of HER2, HER3 and MMPs, and was completely abrogated by combination HER2-HER3 blockade using Herceptin® and the humanized HER3 monoclonal antibody, EV20. Collectively these data suggest mechanisms by which the HER3-HER2 dimer promotes development of metastatic tumors in the heregulin-rich brain microenvironment.


Asunto(s)
Barrera Hematoencefálica/metabolismo , Neoplasias de la Mama/patología , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Neurregulina-1/metabolismo , Receptor ErbB-2/metabolismo , Receptor ErbB-3/metabolismo , Barrera Hematoencefálica/enzimología , Barrera Hematoencefálica/patología , Encéfalo/irrigación sanguínea , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Línea Celular Tumoral , Movimiento Celular/fisiología , Células Endoteliales/metabolismo , Femenino , Humanos , Células MCF-7 , Transducción de Señal
7.
Cancer Immunol Res ; 1(6): 357-61, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24778128

RESUMEN

Patient advocacy organizations play a major role in accelerating research and are particularly important in a disease like melanoma, for which there is an urgent need for new tools and treatments. Melanoma is a growing public health burden. In the United States alone, the incidence of melanoma has tripled over the past 30 years, and one American dies every hour from the disease. To accelerate the field, the Melanoma Research Alliance (MRA) was founded in 2007 and is now the largest private funder of melanoma research, having invested more than $48 million in innovative and translational research projects worldwide to date. This investment is bearing fruit in the recent transformation of the melanoma clinical landscape, which has brought new hope to patients and their families. Yet, even with new drugs on the market, much more needs to be done until melanoma is effectively addressed. MRA is part of a growing group of nonprofit disease research foundations collectively called "venture philanthropies" that are playing a powerful role in transforming the outlook for their disease by overcoming barriers that bog down progress, targeting key areas, and enhancing collaboration. MRA is leading an innovative agenda to accelerate efforts on behalf of patients. Our goal, while significant, is straightforward: to end suffering and death due to melanoma.


Asunto(s)
Investigación Biomédica/organización & administración , Fundaciones/organización & administración , Melanoma/terapia , Defensa del Paciente , Investigación Biomédica/economía , Humanos , Melanoma/epidemiología , Apoyo a la Investigación como Asunto , Estados Unidos/epidemiología
8.
PLoS One ; 7(8): e43041, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22912783

RESUMEN

Caveolin-1 and caveolae are differentially polarized in migrating cells in various models, and caveolin-1 expression has been shown to quantitatively modulate cell migration. PTRF/cavin-1 is a cytoplasmic protein now established to be also necessary for caveola formation. Here we tested the effect of PTRF expression on cell migration. Using fluorescence imaging, quantitative proteomics, and cell migration assays we show that PTRF/cavin-1 modulates cellular polarization, and the subcellular localization of Rac1 and caveolin-1 in migrating cells as well as PKCα caveola recruitment. PTRF/cavin-1 quantitatively reduced cell migration, and induced mesenchymal epithelial reversion. Similar to caveolin-1, the polarization of PTRF/cavin-1 was dependent on the migration mode. By selectively manipulating PTRF/cavin-1 and caveolin-1 expression (and therefore caveola formation) in multiple cell systems, we unveil caveola-independent functions for both proteins in cell migration.


Asunto(s)
Caveolina 1/metabolismo , Movimiento Celular/fisiología , Polaridad Celular/fisiología , Proteínas de la Membrana/metabolismo , Animales , Western Blotting , Movimiento Celular/genética , Polaridad Celular/genética , Quimiotaxis/fisiología , Ratones , Microscopía Fluorescente , Microscopía por Video , Células 3T3 NIH , Neuropéptidos/metabolismo , Proteínas de Unión al ARN , Proteínas de Unión al GTP rac/metabolismo , Proteína de Unión al GTP rac1
9.
J Neurosci ; 28(20): 5240-7, 2008 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-18480280

RESUMEN

The regulated production of neurons in the hippocampus throughout life underpins important brain functions such as learning and memory. Surprisingly, however, studies have so far failed to identify a resident hippocampal stem cell capable of providing the renewable source of these neurons. Here, we report that depolarizing levels of KCl produce a threefold increase in the number of neurospheres generated from the adult mouse hippocampus. Most interestingly, however, depolarizing levels of KCl led to the emergence of a small subpopulation of precursors (approximately eight per hippocampus) with the capacity to generate very large neurospheres (> 250 microm in diameter). Many of these contained cells that displayed the cardinal properties of stem cells: multipotentiality and self-renewal. In contrast, the same conditions led to the opposite effect in the other main neurogenic region of the brain, the subventricular zone, in which neurosphere numbers decreased by approximately 40% in response to depolarizing levels of KCl. Most importantly, we also show that the latent hippocampal progenitor population can be activated in vivo in response to prolonged neural activity found in status epilepticus. This work provides the first direct evidence of a latent precursor and stem cell population in the adult hippocampus, which is able to be activated by neural activity. Because the latent population is also demonstrated to reside in the aged animal, defining the precise mechanisms that underlie its activation may provide a means to combat the cognitive deficits associated with a decline in neurogenesis.


Asunto(s)
Potenciales de Acción/fisiología , Hipocampo/fisiología , Neuronas/fisiología , Células Madre/fisiología , Transmisión Sináptica/fisiología , Potenciales de Acción/efectos de los fármacos , Envejecimiento/patología , Animales , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Trastornos del Conocimiento/tratamiento farmacológico , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/fisiopatología , Hipocampo/citología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Plasticidad Neuronal/efectos de los fármacos , Plasticidad Neuronal/fisiología , Neuronas/citología , Neuronas/efectos de los fármacos , Cloruro de Potasio/farmacología , Esferoides Celulares , Células Madre/citología , Células Madre/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...